Modality
Multispecific
MOA
SOS1i
Target
EZH2
Pathway
mTOR
IgANAsthmaFTD
Development Pipeline
Preclinical
~Jun 2017
→ ~Sep 2018
Phase 1
~Dec 2018
→ ~Mar 2020
Phase 2
~Jun 2020
→ ~Sep 2021
Phase 3
~Dec 2021
→ ~Mar 2023
NDA/BLA
Jun 2023
→ Jan 2029
NDA/BLACurrent
NCT08520516
351 pts·FTD
2023-06→2029-01·Completed
351 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-152.8y awayPh3 Readout· FTD
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2029-01-15 · 2.8y away
FTD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08520516 | NDA/BLA | FTD | Completed | 351 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 |